![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Moderna’s COVID-19 Vaccine Grabs Fast-Track Designation from FDA
Moderna’s COVID-19 Vaccine Grabs Fast-Track Designation from FDA
![Moderna logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Moderna-logo.jpg?t=1589311392&width=430)
The FDA has granted Moderna’s COVID-19 vaccine candidate a fast-track designation, making it the first potential vaccine to receive the agency’s expedited review status.
The company is finalizing the protocol for a phase 3 study of the vaccine, mRNA-1273. The phase 3 trial is expected to begin in early summer.
Moderna previously received fast-track designations for three other messenger RNA vaccine programs, including its investigational Zika vaccine.
Upcoming Events
-
21Oct